Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2003
08/21/2003US20030158149 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold
08/21/2003US20030158133 Use of such inhibitors or activators in treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments
08/21/2003US20030158130 Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
08/21/2003US20030158126 Plant compounds menthol and menthyl acetate when mixed at specific concentrations enhance antifungal activity of commercially available fungicides
08/21/2003US20030158121 Novel $G(y)crystalline form of perindopril tert- butylamine salt, preparation method, and pharmaceutical compositions containing same
08/21/2003US20030158120 Combination product comprising melagatran and a factor xa inhibitor
08/21/2003US20030158119 Combination product of a 1,4-benzothiepine 1,1-dioxide compound with at least on
08/21/2003US20030158114 Administering to a subject in need of such treatment, an agent in an amount effective to inhibit proliferation
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030158097 P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
08/21/2003US20030158094 Combination product of an aryl-substituted propanolamine derivative with at least one other active ingredient and the use of the product
08/21/2003US20030158087 Novel use of fulmonary surfactant for the prophylaxis or early treatment if acute fulmonary diseases
08/21/2003US20030158081 Genetic polymorphisms in the human HMG-CoA reductase gene and their use in diagnosis and treatment of diseases
08/21/2003US20030157704 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
08/21/2003US20030157649 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
08/21/2003US20030157633 Comprises nucleotide sequences coding transmembrane protein/transport protein (TRPV3) for treating pain, inflammation and skin disorders
08/21/2003US20030157573 Use of Axl receptor for diagnosis and treatment of renal disease
08/21/2003US20030157560 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
08/21/2003US20030157552 Providing a screening assay having stearoyl-CoA desaturase biological activity, contacting sceening assay with a test compound and measuring the biological activity
08/21/2003US20030157531 TAOJIKs as modifiers of the beta-catenin pathway and methods of use
08/21/2003US20030157502 Induce apoptosis; antitumor, anticancer agents
08/21/2003US20030157485 Forensic analysis; chromosome marking
08/21/2003US20030157482 Binding labeled antibody to protein; measurement; calibration
08/21/2003US20030157238 Blended baby foods
08/21/2003US20030157200 Use of oligosaccharides to stimulate beta-endorphin production
08/21/2003US20030157195 Composition and method for treating diaper rashes and skin irritations caused by acidic secretions
08/21/2003US20030157191 Administering to a subject undergoing chemotherapy an amount of a chemoprotectant
08/21/2003US20030157178 Injectable depot composition
08/21/2003US20030157142 Implants with a phosphazene-containing coating
08/21/2003US20030157140 Parenteral preparation having structure of basement polymer layer, carrying layer containing objective substances selected from drugs, aroma chemicals, antigens; carrying layer sandwiched between basement and surface layers
08/21/2003US20030157138 Pharmaceutical or cosmetic carrier or composition for topical application onto skin and/or mucosal membranes; treatment of skin diseases or disorders including eczema, psoriasis and dermatitis
08/21/2003US20030157118 Tumour-specific animal proteins
08/21/2003US20030157104 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
08/21/2003US20030157102 Administering a ligand having a population of activated t cells and binding specificity for the extracellular domain of CD28 to enhance t cell proliferation and increase overall lymphokine levels
08/21/2003US20030157098 Methods for inhibiting brain tumor growth
08/21/2003US20030157095 Invasive and metastic ability of breast cancer cells is proportional to level of peripheral type benzodiazepine receptor expressed, correlates with subcellular localization in that it is found in the nucleus of aggressive tumor cells
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157083 Mixture with gelatin capsules; low temperature; human absorption
08/21/2003US20030157082 Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
08/21/2003US20030157055 Modified cytokines for use in cancer therapy
08/21/2003US20030157053 Administering mixture of apotosis agent and neutralizer thereof
08/21/2003US20030157029 Methods of administering and enhancing absorption of pharmaceutical agents
08/21/2003DE19937304C2 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists for the control of menopausal hot flushes
08/21/2003CA2516331A1 Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476446A1 Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
08/21/2003CA2476366A1 Cancer therapy
08/21/2003CA2476292A1 Helical peptidomimetics
08/21/2003CA2476282A1 Dosing regimen for gemcitabine hcv therapy
08/21/2003CA2476279A1 Modified fluorinated nucleoside analogues
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476120A1 Methods and compositions for the treatment of eye diseases
08/21/2003CA2476000A1 Methods and compositions for treating hyperproliferative conditions
08/21/2003CA2475928A1 Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds
08/21/2003CA2475882A1 Alpha-substituted heteroarylalkyl phosphonate derivatives
08/21/2003CA2475770A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
08/21/2003CA2475768A1 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
08/21/2003CA2475763A1 Methods of treating attention deficit/hyperactivity disorder (adhd)
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003CA2475522A1 Method of radio-labelling biomolecules
08/21/2003CA2475338A1 Treatment of ophthalmic disorders using urea and urea derivatives
08/21/2003CA2474885A1 Mutated gene coding for a lat protein and the biological applications thereof
08/21/2003CA2474171A1 Biphenil derivatives and their use as antiandrogenic agents
08/21/2003CA2473586A1 Treatment of sleep disorders using sleep target modulators
08/21/2003CA2462688A1 Partial dopamine-d2 receptor agonist plus serotonin and/or noradrenaline inhibitor activity
08/21/2003CA2372785A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
08/20/2003EP1336619A2 Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
08/20/2003EP1336607A1 Amide derivatives as glucokinase activators
08/20/2003EP1336600A2 Dimer-selective RXR modulators and methods for their use
08/20/2003EP1336413A1 Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
08/20/2003EP1336412A1 Combinations of an antibiotic and a murein hydrolase inhibitor
08/20/2003EP1336409A1 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
08/20/2003EP1336407A1 Medicinal compositions
08/20/2003EP1336406A1 Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
08/20/2003EP1335976A2 Modifier of organelle metalbolism
08/20/2003EP1335937A2 Mixed fibrils
08/20/2003EP1335920A2 Small molecule compositions for binding to hsp90
08/20/2003EP1335747A1 A composition of sodium channel blocking compound
08/20/2003EP1335745A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer
08/20/2003EP1335736A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders
08/20/2003EP1335734A1 Method for treating hiv
08/20/2003EP1335733A1 Treatment of osteoporosis
08/20/2003EP1335731A2 Antidiabetic compositions containing a biguanide and a sulfonamide
08/20/2003EP1335730A1 Treatment of premature ejaculation
08/20/2003EP1335729A2 Inhalative solution formulation containing a tiotropium salt
08/20/2003EP1335726A1 Modified prodrug forms of ap/amp
08/20/2003EP1335723A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis
08/20/2003EP1335721A2 Method of treating and preventing migraine headaches
08/20/2003EP1335717A1 Treatment of pcp addiction and pcp addiction-related behavior
08/20/2003EP1335716A1 Novel use of combined 5-ht 1a agonists and selective serotonin reuptake inhibitors
08/20/2003EP1335711A2 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
08/20/2003EP1335708A1 Controlled release metformin compositions
08/20/2003EP1335701A2 Anti-adiposis topical treatment composition based on garlic bulb extracts
08/20/2003EP1335693A2 Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
08/20/2003EP1335687A2 Method for restoring a damaged or degenerated intervertebral disc
08/20/2003EP1263504B1 Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
08/20/2003EP1146892B1 Baff, inhibitors thereof and their use in the modulation of the b-cell response
08/20/2003EP0966295B1 Calcareous material
08/20/2003EP0874630B1 Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy
1 ... 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 ... 1151